kb111
kb111: developed by 1 company · 1 clinical trial tracked. Updated within the last hour.
Lead developer: Krystal Biotech, Inc. (KRYS)
Development Pipeline (1)
| Company | Phase |
|---|---|
| Krystal Biotech, Inc. (KRYS) | Early Phase 1 |
Clinical Trials (1)
An Open-Label Study to Investigate Safety and Preliminary Efficacy of KB111 for the Treatment of Hailey-Hailey Disease
Frequently asked questions
Who is developing kb111?
kb111 is being developed by Krystal Biotech, Inc..
How many clinical trials involve kb111?
BioSniper tracks 1 clinical trial involving kb111.
Analyze Krystal Biotech, Inc. & kb111 with AI
Full trial data, mechanism of action, competitive landscape, and AI-powered insights.
- 200 free AI credits / month to run live multi-agent analysis
- Watchlist, catalyst alerts & the biotech event calendar
- Full pipeline, financials & FDA data on every company